vTv Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
September 04 2019 - 7:30AM
vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical-stage
biopharmaceutical company focused on the development of orally
administered treatments for diabetes and Alzheimer’s disease, today
announced that it is scheduled to present a general company update
at the H.C. Wainwright 21st Annual Global Investment Conference on
Tuesday, September 10, 2019 at 3:00 p.m. Eastern Time in New York
City. Company management will also be meeting with members of the
investment community during one-on-one meetings at the conference.
A live webcast of the presentation can be accessed here and will
be accessible for 30 days following the presentation at
www.vtvtherapeutics.com.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company focused on developing oral small molecule drug candidates.
vTv has a pipeline of clinical drug candidates led by programs for
the treatment of diabetes, Alzheimer’s disease, and inflammatory
disorders. vTv’s development partners are pursuing additional
indications in type 2 diabetes, COPD, and genetic mitochondrial
diseases.
ContactsInvestors: vTv Therapeutics Inc.
IR@vtvtherapeutics.com
or
Media:Josh Vlasto212-572-5969PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Aug 2024 to Sep 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Sep 2023 to Sep 2024